<h2 dir="ltr"><strong>Huntington's Disease</strong></h2>
<p dir="ltr"><a href="https://www.delveinsight.com/report-store/huntingtons-disease-market"><strong>Huntington's Disease</strong></a> is a rare, inherited, progressive brain disorder caused by a mutation in the HTT gene on chromosome 4, leading to the production of abnormal huntingtin protein and gradual nerve cell damage.</p>
<h3 dir="ltr"><strong>Huntington's Disease Epidemiology Segmentation</strong></h3>
<ul>
<li dir="ltr" role="presentation">Total Prevalent Cases of Huntington's Disease</li>
<li dir="ltr" role="presentation">Total Diagnosed Prevalent Cases of Huntington's Disease</li>
<li dir="ltr" role="presentation">Age-specific Cases of Huntington's Disease</li>
<li dir="ltr" role="presentation">Stage-specific Cases of Huntington's Disease</li>
<li dir="ltr" role="presentation">Total Treated Cases of Huntington's Disease</li>
</ul>
<h2 dir="ltr"><strong>Huntington's Disease Epidemiology</strong></h2>
<ul>
<li dir="ltr" role="presentation">The total prevalent cases of Huntington's Disease across the 7MM were estimated at approximately 83K in 2025.</li>
<li dir="ltr" role="presentation">The United States accounted for approximately 53% of prevalent cases, followed by the EU4 and the UK with 45% and Japan with 2%.</li>
<li dir="ltr" role="presentation">Across the 7MM, Huntington's Disease was more prevalent among individuals aged 60 years and above, accounting for approximately 50% of total cases.</li>
<li dir="ltr" role="presentation">Secondary data indicate that Stage IV and Stage V Huntington's Disease cases remain comparatively low. In Japan, approximately 80 Stage IV cases and 20 Stage V cases were estimated in 2025.</li>
</ul>
<h2 dir="ltr"><strong>Huntington's Disease Market</strong></h2>
<ul>
<li dir="ltr" role="presentation">The Huntington's Disease market across the 7MM was estimated at approximately USD 320 million in 2025.</li>
<li dir="ltr" role="presentation">The Huntington's Disease market is expected to grow at a CAGR of 14% during the forecast period from 2026 to 2036.</li>
<li dir="ltr" role="presentation">AUSTEDO generated the highest revenue among approved therapies, accounting for approximately USD 167 million in 2025.</li>
<li dir="ltr" role="presentation">The therapeutic landscape is shifting from symptomatic management toward disease-modifying approaches, with gene therapies, antisense oligonucleotides, and RNA-targeted therapies expected to reshape future treatment strategies.</li>
</ul>
<h3 dir="ltr"><strong>Huntington's Disease Market Drivers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Advancements in genetic testing and diagnosis are improving early disease identification.</li>
<li dir="ltr" role="presentation">The emergence of disease-modifying therapies is transforming the treatment landscape.</li>
<li dir="ltr" role="presentation">Increasing research funding and disease awareness are accelerating therapeutic development.</li>
<li dir="ltr" role="presentation">Improved understanding of Huntington's Disease biology is supporting innovation in targeted therapies.</li>
</ul>
<h3 dir="ltr"><strong>Huntington's Disease Market Barriers</strong></h3>
<ul>
<li dir="ltr" role="presentation">The absence of approved disease-modifying therapies remains a major unmet clinical need.</li>
<li dir="ltr" role="presentation">Current treatment options provide limited benefit for cognitive decline associated with Huntington's Disease.</li>
<li dir="ltr" role="presentation">Significant gaps remain in the management of psychiatric symptoms and behavioral complications.</li>
<li dir="ltr" role="presentation">Delayed diagnosis and challenges in predicting disease progression continue to impact patient outcomes.</li>
</ul>
<h3 dir="ltr"><strong>Emerging Huntington's Disease Drugs</strong></h3>
<ul>
<li dir="ltr" role="presentation">SKY-0515</li>
<li dir="ltr" role="presentation">Votoplam (PTC518)</li>
<li dir="ltr" role="presentation">And others</li>
</ul>
<h3 dir="ltr"><strong>Key Huntington's Disease Companies</strong></h3>
<ul>
<li dir="ltr" role="presentation">Teva Pharmaceuticals</li>
<li dir="ltr" role="presentation">Neurocrine Biosciences</li>
<li dir="ltr" role="presentation">Skyhawk Therapeutics</li>
<li dir="ltr" role="presentation">Novartis Pharmaceuticals</li>
<li dir="ltr" role="presentation">PTC Therapeutics</li>
<li dir="ltr" role="presentation">uniQure</li>
<li dir="ltr" role="presentation">Wave Life Sciences</li>
<li dir="ltr" role="presentation">Roche</li>
<li dir="ltr" role="presentation">Prilenia Therapeutics</li>
<li dir="ltr" role="presentation">Voyager Therapeutics</li>
<li dir="ltr" role="presentation">And others</li>
</ul>

Huntington's disease Market

Huntington's disease Market Infograhics

 Huntington's disease Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape